drugset / Trial / NCT06513221
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, multi-arm, phase II clinical trial that uses transcriptome profiling to guide the evaluation of the efficacy of multiple lines of standard chemotherapy and bevacizumab combined with adebrelimab in patients with MSS-type metastatic colorectal cancer, aiming to expand the immunotherapy cohort while accurately narrowing the population of MSS-type colorectal cancer that benefits from immunity. This study includes a screening period, a treatment period, and a follow-up period.
Timeline
- Start
- 2024-07-25
- Primary completion
- 2026-04-01
- Completion
- 2027-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |